Pacific Biosciences (PACB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 56,060 | 78,672 | 99,868 | 76,946 | 180,211 |
| Marketable Securities | 334,561 | 393,165 | 410,276 | 485,268 | 451,505 |
| Receivables | 27,524 | 29,383 | 32,433 | 30,323 | 36,615 |
| Inventories | 58,755 | 65,737 | 68,594 | 67,343 | 56,676 |
| TOTAL | $495,681 | $584,234 | $628,139 | $677,024 | $742,047 |
| Non-Current Assets | |||||
| PPE Net | 30,505 | 31,952 | 34,910 | 37,291 | 36,432 |
| Intangibles | 707,333 | 805,487 | 812,339 | 912,392 | 919,245 |
| Other Non-Current Assets | 26,928 | 28,379 | 34,103 | 43,213 | 48,289 |
| TOTAL | $764,766 | $865,818 | $881,352 | $992,896 | $1,003,966 |
| Total Assets | $1,260,447 | $1,450,052 | $1,509,491 | $1,669,920 | $1,746,013 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 16,590 | 12,064 | 17,488 | 21,006 | 15,062 |
| Accrued Expenses | 22,595 | 19,183 | 22,456 | 21,991 | 45,708 |
| Other current liabilities | 3,224 | 783 | 6,747 | 2,836 | 8,326 |
| TOTAL | $66,299 | $59,997 | $78,390 | $72,951 | $95,029 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 13,864 | 17,292 | 19,212 | 17,346 | 16,342 |
| Other Non-Current Liabilities | 681,654 | 931,478 | 932,695 | 941,825 | 944,150 |
| TOTAL | $687,554 | $936,933 | $938,401 | $947,952 | $949,680 |
| Total Liabilities | $753,853 | $996,930 | $1,016,791 | $1,020,903 | $1,044,709 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 297,852 | 273,864 | 272,529 | 272,356 | 267,952 |
| Common Shares | 294 | 274 | 272 | 272 | 268 |
| Retained earnings | -2,148,926 | -2,151,297 | -2,090,572 | -1,917,253 | -1,839,075 |
| Other shareholders' equity | 422 | 1,553 | -523 | -306 | 219 |
| TOTAL | $506,594 | $453,122 | $492,700 | $649,017 | $701,304 |
| Total Liabilities And Equity | $1,260,447 | $1,450,052 | $1,509,491 | $1,669,920 | $1,746,013 |